Compare British American Tobacco PLC (BTI) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Danaher Corporation — how do they compare? British American Tobacco PLC trades at $56.65 (market cap $122.36B), while Danaher Corporation trades at $207.23 (market cap $145.83B). The key difference: Danaher Corporation is the larger of the two by market cap, and British American Tobacco PLC pays the higher dividend (5.88%). Which is the better fit depends on your goals.
| BTI | DHR | |
|---|---|---|
Market Cap | $122.36B | $145.83B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $242.05 |
52-Week Low | $50.39 | $161.91 |
Enterprise Value | $166.31B | $168.04B |
Dividend Yield | 5.88% | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTI trades at $57.05, down 3.84% in the past 24 hours, with a bearish technical signal but strong fundamentals including a 24.99% net income margin and 13.33% ROE. Recent earnings show three beats out of four quarters, while cash flow turned negative in 2025. The company is pivoting to next-generation nicotine products like Velo, supported by a multi-year tech partnership with ITC Infotech announced in August 2026.
The outlook is mixed: valuation appears reasonable with a P/E of 14.48, and analyst consensus is 66.7% buy ratings, but technical indicators are bearish and regulatory risks persist. The stock offers income potential with dividends, yet faces headwinds from declining combustibles and recent workforce cuts.
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
